Dr. rer. nat. Thomas Günther

Scientific co-worker, Habilitation Candidate

Thomas Günther studied chemistry at the Technichal University of Munich and worked on the synthesis and labeling of Somatostatin receptor ligands for his Bachelor's Thesis.
This was followed by his Master studies at the TU Munich. For his Master's Thesis, he tried to optimize the lipophilic properties of Cy5-based fluorescence dyes by attaching carbohydrates.
During his PhD study, he worked on the development of novel GRPR-targeted antagonists for enhanced imaging and targeted radiotherapy of prostate and breast cancers. Since 2020, he is working on the development of novel CCK-2R-addressing compounds for imaging and targeted radiotherapy of medullary thyroid cancer.

Financial Support

Funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - 461577150, Module Temporary Positions for Principal Investigators, Project: Novel Radiohybrid-based CCK-2R-targeted Ligands for Imaging and Targeted Radiotherapy of Medullary Thyroid Cancer

Teaching

• Pharmaceutical Radiochemistry I (CH3301)
• Parts of Pharmaceutical Radiochemistry II (CH3302)
• Parts of the Seminar for the Research Internship with Seminar and Lecture (CH3304b)
• Parts of the Lecture for the Research Internship with Seminar and Lecture (CH3304c)
• Head of the Internship Radioactivity, Radioanalytics and Production of Radiopharmaceuticals (CH3303b)

Publications

• Substitution of L-Trp by α-methyl-L-Trp in ¹⁷⁷Lu-RM2 results in ¹⁷⁷Lu-AMTG, a high affinity GRPR ligand with improved in vivo stability; Guenther T, Deiser S, Felber V, Beck R, Wester HJ. Journal of Nuclear Medicine January 2022, jnumed.121.263323; DOI: https://doi.org/10.2967/jnumed.121.263323

• Development and preclinical evaluation of ¹⁷⁷Lu-AMTG, a novel pharmacophore-modified GRPR-targeted antagonist with improved metabolic stability; Günther, T, Beck, R, Felber, V, Deiser, S, Wester, HJ. European Association of Nuclear Medicine October 22 – 30, 2020 Virtual. Eur J Nucl Med Mol Imaging 2020, 47 (Suppl 1): S1–S753.

• Preclinical results of novel GRPR-targeted antagonists with modified binding sequences; Günther T,  Fischer S,  Beck R, Wester, HJ. Journal of Nuclear Medicine 2020, 61 (supplement 1), 1054.

• Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity; Wirtz M, Schmidt A, Schottelius M, Robu S, Günther T, Schwaiger M, Wester HJ. EJNMMI Res. 2018 Aug 22;8(84)

• Synthesis and preclinical evaluation of novel ¹⁸F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with ¹⁸F-DCFPyl and ¹⁸F-PSMA-1007; Robu S, Schmidt A, Eiber M, Schottelius M, Günther T, Yousefi B, Schwaiger M, Wester HJ. EJNMMI Res. 2018 Apr 12;8(1):30